Paclitaxel poliglumex
- Generic Name
- Paclitaxel poliglumex
- Drug Type
- Small Molecule
- CAS Number
- 263351-82-2
- Unique Ingredient Identifier
- TQ64FZ98ZN
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- State University of New York - Upstate Medical University
- Target Recruit Count
- 53
- Registration Number
- NCT00660218
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
A Pilot Study of PPX in Women With Metastatic Colorectal Cancer
- First Posted Date
- 2008-01-21
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 15
- Registration Number
- NCT00598247
- Locations
- 🇺🇸
University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center, Los Angeles, California, United States
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 450
- Registration Number
- NCT00551733
- Locations
- 🇺🇸
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center, Burbank, California, United States
🇺🇸Clinical Trials and Research Associates, Incorporated, Montebello, California, United States
🇺🇸Broward Oncology Associates, Fort Lauderdale, Florida, United States
Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00459810
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT00352690
- Locations
- 🇺🇸
University of Kansas, Lawrence, Kansas, United States
🇺🇸Rush University Medical College, Chicago, Illinois, United States
🇺🇸Washington Hospital Center, Washington, District of Columbia, United States
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
- Conditions
- NSCLC
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 600
- Registration Number
- NCT00269828
- Locations
- 🇦🇷
Hospital General de Agudos "Dr Teodoro Alvarez", Buenos Aires, Argentina
🇦🇷LUCEN, Cuidad Autonoma de Buenos Aires, Argentina
🇦🇷ISIS Clinica Especializada, Urquiza, Argentina
Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 48
- Registration Number
- NCT00265733
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube Endometrioid AdenocarcinomaOvarian Brenner TumorOvarian Clear Cell AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaStage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Primary Peritoneal Cancer AJCC v7Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Undifferentiated Carcinoma
- Interventions
- Other: Clinical ObservationOther: Laboratory Biomarker AnalysisProcedure: Quality-of-Life Assessment
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- GOG Foundation
- Target Recruit Count
- 1157
- Registration Number
- NCT00108745
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸MetroHealth Medical Center, Cleveland, Ohio, United States
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00017017
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
- Conditions
- Ovarian Serous CystadenocarcinomaPrimary Peritoneal CarcinomaOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Brenner TumorFallopian Tube CarcinomaMalignant Ovarian Mixed Epithelial TumorOvarian Mucinous CystadenocarcinomaStage III Ovarian CancerStage IV Ovarian Cancer
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 32
- Registration Number
- NCT00060359
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.